Evidence map›Paper›PMID 41411501›Full record

ArticleMolecular pharmaceutics2026

Mechanism of Self-Assembly of the Gonadropin Releasing Hormone Antagonist Teverelix into Amyloid Fibrils.

Xinyang Li, Louise C Serpell, Jens T Bukrinski, Francois Boutignon, Carol M MacLean, Sophie E Jackson

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinyang LiYusuf Hamied Department of Chemistry, Lensfield Road, Cambridge CB2 1EW, U.K.
Louise C SerpellSussex Neuroscience, School of Life Sciences, University of Sussex, Brighton BN1 9QG, U.K.ORCID 0000-0001-9335-7751
Jens T BukrinskiCMCAssist ApS, Ole Maalo̷es Vej 3, Copenhagen N 2200, Denmark.
Francois BoutignonBoutignon & Partners, 2 rue Michel Renaud, Biopole Clermont-Limagne, Saint Beauzire 63360, France.
Carol M MacLeanAntev Ltd, Ibex House, Baker Street, Weybridge, Surrey KT13 8AH, U.K.
Sophie E JacksonYusuf Hamied Department of Chemistry, Lensfield Road, Cambridge CB2 1EW, U.K.ORCID 0000-0002-7470-9800

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Teverelix is a short non-natural peptide, which is a gonadotropin releasing hormone antagonist and used as a treatment for prostate cancer. Teverelix is formulated as a trifluoroacetic acid salt, which, at the high concentrations used for parenteral injection, forms a microcrystalline suspension. At low concentrations and immediately after injection, teverelix self-assembles into a fibrillar species thought to be important for the slow-release kinetics and long-acting action of this peptide in vivo. In this paper, we confirmed the amyloid-like identity of teverelix fibrils using X-ray fiber diffraction and transmission electron microscopy. The inter-β-sheet packing distance was found to be larger than that of typical amyloid fibrils and this was attributed to the large non-natural side chains within the peptide. Using data from numerous biophysical experiments, a model of the structure of teverelix within the fibril is proposed. The kinetics of fibril formation were investigated using standard ThT assays, and teverelix found to fibrillate rapidly over a wide range of conditions. The fibrillation rate was shown to depend critically upon pH, peptide, and trifluoroacetic acid concentration. Fibrillation was accompanied by a drop in pH, which we attribute to the fact that the pyridinium side chain must be deprotonated before self-assembly. Based on our results, we propose a nucleation-polymerization mechanism in which dimers of teverelix rapidly self-assemble into amyloid-like fibrils with little change in the secondary structure but burial of some of the aromatic acid side chains. Interestingly, the fibrils can, under certain conditions, align to create a highly ordered array. To the best of our knowledge, this is the first paper studying teverelix in detail from a biophysical perspective, and it is directly relevant to the aggregation of the peptide observed in vivo.

Indexed as

AmyloidGonadotropin-Releasing HormoneHumansMaleMicroscopy, Electron, TransmissionOligopeptidesX-Ray Diffractionacetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamideAmyloidGonadotropin-Releasing HormoneOligopeptidesamyloid fibrilsGnRH antagonistnucleation−polymerization mechanismprostate cancerslow-release depottherapeutic peptide

Identifiers

PMID41411501
PMCPMC12776573

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.